Pleural
Leveraging Immunogenic Cell Death to Enhance the Immune Response against Malignant Pleural Mesothelioma Tumors
Journal of the American Chemical Society 2025 March 5 [Link] Meng Rui Chang, Egor M Matnurov, Chengnan Wu, Jemma Arakelyan, Ho-Jung Choe, Vladimir Kushnarev, Jian Yu Yap, Xiu Xuan Soo, Mun Juinn Chow, Walter Berger, Wee Han Ang, Maria V Babak Abstract Although various metal-based compounds have exhibited excellent immunogenic cell death (ICD)-inducing properties both…
Read MoremiRNA-503 inhibition exerts anticancer effects and reduces tumor growth in mesothelioma
Journal of Experimental & Clinical Cancer Research 2025 February 22 [Link] Miriam Piccioni, Francesco Di Meo, Anna Valentino, Virginia Campani, Maddalena Arigoni, Mirella Tanori, Mariateresa Mancuso, Rossana Cuciniello, Marco Tomasetti, Federica Monaco, Gaia Goteri, Enrico P Spugnini, Raffaele A Calogero, Giuseppe De Rosa, Gianfranco Peluso, Alfonso Baldi, Stefania Crispi Abstract Background: Malignant mesothelioma (MM) is…
Read MoreThe phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes
Journal of Translational Medicine 2025 February 20 [Link] Federica Torricelli, Filomena Spada, Cynthia Bishop, Katrina Todd, Daisuke Nonaka, Nedyalko Petrov, Manuela Terranova Barberio, Alan G Ramsay, Richard Ellis, Alessia Ciarrocchi, Benedetta Apollonio, Andrea Billè Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with limited therapeutic options. To improve patients management and…
Read MoreCD276 as a critical independent biomarker and immune checkpoint inhibitor target in epithelioid mesothelioma-TCGA study
Journal of Thoracic Disease 2025 January 24 [Link] Yuko Aoki, Ken Arimura, Kenzo Hiroshima, Yasuto Sato, Mitsuko Kondo, Etsuko Tagaya Abstract Background: CD276 is an immune checkpoint, and immune checkpoint inhibitors (ICIs) targeting CD276 have been tested against various cancers. However, the precise role of CD276 in mesothelioma subtypes is unknown. This study aimed to…
Read MoreDNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
Journal of Experimental & Clinical Cancer Research 2025 February 18 [Link] Maria Fortunata Lofiego, Rossella Tufano, Emma Bello, Laura Solmonese, Francesco Marzani, Francesca Piazzini, Fabrizio Celesti, Francesca Pia Caruso, Teresa Maria Rosaria Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Luana Calabrò, Michele Maio, Sandra Coral, Anna Maria Di Giacomo, Alessia Covre Abstract Background: Co-targeting of…
Read MorePotential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions
Translational Lung Cancer Research 2025 January 24 [Link] Tian Mun Chee, Caeli J Zahra, Kwun M Fong, Ian A Yang, Rayleen V Bowman Abstract Background: Cytological examination is of suboptimal sensitivity but high specificity for the diagnosis of malignant pleural effusions (MPEs). Pleural fluid extracellular vesicles (PFEVs) are enriched with disease-specific microRNAs (miRNAs) which may…
Read MorePrognostic Stratification of Epithelioid Pleural Mesothelioma Based on the Hippo-TEADs Network
Cancers 2025 January 30 [Link] Anello Marcello Poma, Rossella Bruno, Iacopo Petrini, Iosè Di Stefano, Alessandra Celi, Andrea Sbrana, Sabrina Cappelli, Antonio Chella, Franca Melfi, Marco Lucchi, Greta Alì Abstract Background. The Hippo pathway is the most frequently altered signaling in pleural mesothelioma (PM). Epithelioid PM (ePM) is associated with better outcome than non-epithelioid subtypes,…
Read MoreDiagnostic Challenges in the Pathological Approach to Pleural Mesothelioma
Cancers 2025 February 1 [Link] Stefano Lucà, Giovanna Pignata, Alessandro Cioce, Cecilia Salzillo, Rossella De Cecio, Gerardo Ferrara, Carminia Maria Della Corte, Floriana Morgillo, Alfonso Fiorelli, Marco Montella, Renato Franco Abstract Malignant pleural mesothelioma (MPM) still represents a complex diagnostic challenge for pathologists in routine practice. This diagnosis requires a multidisciplinary approach, and pathological evaluation…
Read MoreTumor Treating Fields enhance chemotherapy efficacy by increasing cellular drug uptake and retention in mesothelioma cells
American Journal of Cancer Research 2025 January 15 [Link] Rosy Amodeo, Lavinia Morosi, Marina Meroni, Ezia Bello, Sara Timo, Roberta Frapolli, Maurizio D’Incalci, Monica Lupi Abstract Tumor Treating Fields (TTFields) applied with standard chemotherapy have been approved for the first-line treatment of unresectable pleural mesothelioma (PM), an aggressive malignancy with limited effective therapy options. In…
Read MoreCurrent Status of Staging and Restaging Malignant Pleural Mesothelioma
Seminars in Nuclear Medicine 2025 March [Link] Egesta Lopci Malignant pleural mesothelioma (MPM) is the most frequent aggressive tumor affecting the pleura, accounting for over 38,000 deaths worldwide. It originates from the mesothelial cells and is mostly associated to asbestos exposure. Depending on the extent of the disease, the management of MPM varies from surgical…
Read More